Sign in Subscribe
Software industry

Agilent Technologies Introduces SurePrint G3 CGH+SNP Cancer Catalog Microarrays

Strategic Insights

— 1 min read

Researchers in cancer genomics have a growing need to detect both copy number and copy-neutral aberrations in cancer tissue samples, a challenge that Agilent Technologies Inc. addresses with its new SurePrint G3 CGH+SNP cancer catalog microarrays. This new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which includes support for CGH+SNP analysis of genetically complex samples like hematological cancer samples. The new microarrays are based on designs by the Cancer Cytogenomics Microarray Consortium and join Agilent's market-leading CGH+SNP microarrays and ISCA arrays for cytogenetic research.

Key Takeaways:

  • The new SurePrint G3 CGH+SNP cancer catalog microarrays allow researchers to detect both copy number and copy-neutral aberrations in cancer tissue samples in a single experiment.
  • The microarrays are designed by the Cancer Cytogenomics Microarray Consortium and join Agilent's market-leading CGH+SNP microarrays and ISCA arrays for cytogenetic research.
  • The new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which includes support for CGH+SNP analysis of genetically complex samples like hematological cancer samples.
  • The new software algorithms allow analysis of samples with genomic complexity, tumor heterogeneity, and admixtures of tumor and normal cells.
  • Agilent offers easy customization of SurePrint G3 CGH+SNP cancer arrays, allowing customers to choose from 65,000 SNPs and more than 28 million prequalified CGH probes.
  • The company's comprehensive genomics workflow solutions include the Bravo automated liquid-handling platform, new generation SureScan Microarray Scanner, reagents, and bioinformatics software.

Statistics:

  • The new microarrays detect both copy number and copy-neutral aberrations with approximately 5-Mb LOH resolution.
  • The SurePrint G3 CGH+SNP cancer catalog microarrays are designed to support analysis of samples with genomic complexity, tumor heterogeneity, and admixtures of tumor and normal cells.
  • Agilent's eArray online design tool allows customers to choose from 65,000 SNPs and more than 28 million prequalified CGH probes.
  • The new CytoGenomics 2.0 software is available at no charge to array customers.

Sources:

  • Agilent Technologies Inc.
  • Cancer Cytogenomics Microarray Consortium
  • Baylor College of Medicine
  • Agilent senior marketing director, Genomics
  • Agilent Technologies Inc.

Read more